Prolonged Clinical Follow-up of OPTIMA-5
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.
Also called NCT05649696
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 210 participants
- Registry
-
NCT05649696
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05649696. Randomized; triple masking; primary purpose treatment. Start 2021-10-29 (actual); primary completion 2023-09-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prolonged Clinical Follow-up of OPTIMA-5
- Condition
- ST-segment Elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- Recombinant Staphylokinase
- Intervention (Drug)
- Normal Saline
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
Record details
- Record id
cardio:ct-nct05649696- Content hash
651e444b6e0c7c6255560b1574df3be86776a9b7dbef825b81bb6997a3ce8bf1